^
Association details:
Biomarker:miR-96 expression
Cancer:Thyroid Gland Carcinoma
Drug:PLX4720 (BRAF inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: D – Preclinical
New
Source:
Title:

Genome-Wide Analysis of Differentially Expressed miRNA in PLX4720-resistant and Parental Human Thyroid Cancer Cell Lines

Excerpt:
...miRNAs included the top two up-regulated miRNAs: hsa-miR-363-3p and hsa-miR-96-5p, the randomly chosen hsa-miR-21-5p, two of the most down-regulated miRNAs: hsa-miR-1291 and hsa-miR-184 and the 2 novel miRNAs (Table 1 and Supp. Table S2). The qRT-PCR results followed the same pattern of expression changes as observed with the deep sequencing data in 8505c-R cells indicating the reliability of our RNA-Seq data (Fig. 3). Expression levels of these miRNAs except for miR-1291 in BCPAP-R, correlated with that in 8505c-R, suggesting that these miRNAs can be potentially used as markers of resistance in papillary thyroid cancer as well (Fig. 3).
DOI:
10.1016%2Fj.surg.2015.06.046